Applied Dna Sciences Inc (APDN)

$0.32

-0.03

(-8.29%)▲

Market is closed - opens 7 PM, 11 Oct 2024

Performance

  • $0.32
    $0.35
    $0.32
    downward going graph

    1.56%

    Downside

    Day's Volatility :9.69%

    Upside

    8.26%

    downward going graph
  • $0.31
    $22.80
    $0.32
    downward going graph

    2.16%

    Downside

    52 Weeks Volatility :98.63%

    Upside

    98.6%

    downward going graph

Returns

PeriodApplied Dna Sciences IncIndex (Russel 2000)
3 Months
-24.73%
0.0%
6 Months
-95.56%
0.0%
1 Year
-98.38%
0.0%
3 Years
-99.63%
-20.8%

Highlights

Market Capitalization
3.6M
Book Value
$1.2
Earnings Per Share (EPS)
-7.5
PEG Ratio
0.0
Wall Street Target Price
1.5
Profit Margin
-214.48%
Operating Margin TTM
-419.64%
Return On Assets TTM
-57.44%
Return On Equity TTM
-76.08%
Revenue TTM
3.4M
Revenue Per Share TTM
2.2
Quarterly Revenue Growth YOY
-72.7%
Gross Profit TTM
5.1M
EBITDA
-14.0M
Diluted Eps TTM
-7.5
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.92
EPS Estimate Next Year
-1.04
EPS Estimate Current Quarter
-0.35
EPS Estimate Next Quarter
-0.3

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Applied Dna Sciences Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 368.75%

Current $0.32
Target $1.50

Company Financials

FY18Y/Y Change
Revenue
3.9M
↓ 17.85%
Net Income
-11.7M
↓ 9.05%
Net Profit Margin
-299.56%
↓ 28.98%
FY19Y/Y Change
Revenue
5.4M
↑ 38.06%
Net Income
-8.6M
↓ 26.17%
Net Profit Margin
-160.18%
↑ 139.38%
FY20Y/Y Change
Revenue
1.9M
↓ 64.16%
Net Income
-12.8M
↑ 47.87%
Net Profit Margin
-660.89%
↓ 500.71%
FY21Y/Y Change
Revenue
9.0M
↑ 367.4%
Net Income
-16.0M
↑ 25.57%
Net Profit Margin
-177.56%
↑ 483.33%
FY22Y/Y Change
Revenue
18.2M
↑ 101.25%
Net Income
-8.4M
↓ 47.73%
Net Profit Margin
-46.11%
↑ 131.45%
FY23Y/Y Change
Revenue
13.4M
↓ 26.43%
Net Income
-9.9M
↑ 18.73%
Net Profit Margin
-74.41%
↓ 28.3%
Q1 FY23Q/Q Change
Revenue
4.4M
↓ 16.25%
Net Income
588.3K
↓ 115.31%
Net Profit Margin
13.35%
↑ 86.38%
Q2 FY23Q/Q Change
Revenue
2.9M
↓ 33.81%
Net Income
-3.1M
↓ 626.86%
Net Profit Margin
-106.25%
↓ 119.6%
Q3 FY23Q/Q Change
Revenue
779.7K
↓ 73.27%
Net Income
-3.6M
↑ 15.89%
Net Profit Margin
-460.7%
↓ 354.45%
Q4 FY23Q/Q Change
Revenue
891.2K
↑ 14.29%
Net Income
-1.2M
↓ 67.07%
Net Profit Margin
-132.73%
↑ 327.97%
Q1 FY24Q/Q Change
Revenue
929.6K
↑ 4.32%
Net Income
-4.5M
↑ 277.94%
Net Profit Margin
-480.89%
↓ 348.16%
Q2 FY24Q/Q Change
Revenue
797.5K
↓ 14.21%
Net Income
1.9M
↓ 142.05%
Net Profit Margin
235.71%
↑ 716.6%
FY18Y/Y Change
Total Assets
5.6M
↓ 30.91%
Total Liabilities
4.9M
↑ 276.52%
FY19Y/Y Change
Total Assets
3.6M
↓ 36.73%
Total Liabilities
4.4M
↓ 9.55%
FY20Y/Y Change
Total Assets
11.3M
↑ 218.15%
Total Liabilities
5.6M
↑ 27.61%
FY21Y/Y Change
Total Assets
14.4M
↑ 27.12%
Total Liabilities
3.3M
↓ 41.34%
FY22Y/Y Change
Total Assets
22.3M
↑ 54.44%
Total Liabilities
9.4M
↑ 183.19%
FY23Y/Y Change
Total Assets
13.7M
↓ 38.69%
Total Liabilities
8.8M
↓ 6.17%
Q1 FY23Q/Q Change
Total Assets
19.2M
↓ 5.53%
Total Liabilities
9.2M
↓ 17.34%
Q2 FY23Q/Q Change
Total Assets
15.8M
↓ 17.66%
Total Liabilities
8.6M
↓ 6.64%
Q3 FY23Q/Q Change
Total Assets
13.7M
↓ 13.54%
Total Liabilities
8.8M
↑ 2.14%
Q4 FY23Q/Q Change
Total Assets
9.9M
↓ 27.38%
Total Liabilities
5.8M
↓ 34.11%
Q1 FY24Q/Q Change
Total Assets
9.2M
↓ 7.44%
Total Liabilities
9.4M
↑ 61.65%
Q2 FY24Q/Q Change
Total Assets
16.7M
↑ 81.9%
Total Liabilities
4.5M
↓ 52.35%
FY18Y/Y Change
Operating Cash Flow
-6.9M
↓ 7.51%
Investing Cash Flow
-266.0K
↑ 82.9%
Financing Cash Flow
5.9M
↓ 3.64%
FY19Y/Y Change
Operating Cash Flow
-6.9M
↓ 0.8%
Investing Cash Flow
-67.4K
↓ 74.65%
Financing Cash Flow
5.8M
↓ 0.92%
FY20Y/Y Change
Operating Cash Flow
-11.1M
↑ 62.39%
Investing Cash Flow
-1.1M
↑ 1477.3%
Financing Cash Flow
19.4M
↑ 233.43%
FY21Y/Y Change
Operating Cash Flow
-13.4M
↑ 20.15%
Investing Cash Flow
-2.5M
↑ 139.61%
Financing Cash Flow
14.7M
↓ 24.34%
FY22Y/Y Change
Operating Cash Flow
-9.0M
↓ 32.95%
Investing Cash Flow
-489.6K
↓ 80.79%
Financing Cash Flow
18.1M
↑ 23.27%
Q1 FY23Q/Q Change
Operating Cash Flow
214.4K
↓ 109.0%
Investing Cash Flow
-161.8K
↓ 459.56%
Financing Cash Flow
0.0
-
Q2 FY23Q/Q Change
Operating Cash Flow
-1.4M
↓ 738.65%
Investing Cash Flow
-161.8K
↑ 0.0%
Financing Cash Flow
0.0
-

Technicals Summary

Sell

Neutral

Buy

Applied Dna Sciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Applied Dna Sciences Inc
Applied Dna Sciences Inc
-72.66%
-95.56%
-98.38%
-99.63%
-99.81%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-4.29%
-5.85%
5.31%
-22.54%
74.35%
Agilent Technologies Inc.
Agilent Technologies Inc.
4.9%
0.44%
27.81%
-3.48%
95.68%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.0%
4.45%
20.78%
3.56%
113.51%
Danaher Corp.
Danaher Corp.
-2.0%
9.5%
23.1%
-9.88%
94.03%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-2.73%
-4.44%
13.54%
-4.78%
57.91%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Applied Dna Sciences Inc
Applied Dna Sciences Inc
NA
NA
0.0
-6.92
-0.76
-0.57
NA
1.2
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
47.18
47.18
5.0
10.57
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
30.04
30.04
3.12
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.17
37.17
2.22
21.73
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
49.49
49.49
2.66
7.59
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.67
29.67
1.12
11.2
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Applied Dna Sciences Inc
Applied Dna Sciences Inc
Buy
$3.6M
-99.81%
NA
-214.48%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.1B
74.35%
47.18
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.6B
95.68%
30.04
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$228.9B
113.51%
37.17
14.69%
Danaher Corp.
Danaher Corp.
Buy
$194.4B
94.03%
49.49
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$41.7B
57.91%
29.67
9.39%

Insights on Applied Dna Sciences Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 929.63K → 797.51K (in $), with an average decrease of 14.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -4.47M → 1.87M (in $), with an average increase of 337.8% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 27.8% return, outperforming this stock by 126.2%

  • Vs TMO

    In the last 3 years, Applied Dna Sciences Inc has experienced a drawdown of -99.6%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 94.6%

Institutional Holdings

  • AMH Equity Ltd

    6.31%

  • Altium Capital Management, LP

    0.84%

  • Sabby Management LLC

    0.68%

  • Virtu Financial LLC

    0.18%

  • Ground Swell Capital, LLC

    0.15%

  • XTX Topco Ltd

    0.10%

Company Information

we keep life real and safe by providing botanical-dna based security and authentication solutions and services that protect assets, products, brands, supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Organization
Applied Dna Sciences Inc
Employees
52
CEO
Dr. James A. Hayward Ph.D., Sc.D.
Industry
Information Technology Services

Discover More

FAQs